ArticleOncotarget2015

MiR-215, an activator of the CTNNBIP1/β-catenin pathway, is a marker of poor prognosis in human glioma.

Yong-Qing Tong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.